Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization (2016 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $118.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 11.08% year-over-year to $118.3 million, compared with a TTM value of $118.3 million through Dec 2025, up 11.08%, and an annual FY2025 reading of $118.3 million, up 11.08% over the prior year.
- Accumulated Depreciation & Amortization was $118.3 million for Q4 2025 at Neurocrine Biosciences, up from $106.5 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $118.3 million in Q4 2025 and bottomed at $83.0 million in Q4 2023.
- Average Accumulated Depreciation & Amortization over 3 years is $102.6 million, with a median of $106.5 million recorded in 2024.
- The sharpest move saw Accumulated Depreciation & Amortization increased 28.31% in 2024, then increased 11.08% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $83.0 million in 2023, then grew by 28.31% to $106.5 million in 2024, then rose by 11.08% to $118.3 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for NBIX at $118.3 million in Q4 2025, $106.5 million in Q4 2024, and $83.0 million in Q4 2023.